These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 3923041)

  • 1. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
    Hanson SR; Harker LA; Bjornsson TD
    J Clin Invest; 1985 May; 75(5):1591-9. PubMed ID: 3923041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention.
    Harker LA; Hanson SR
    J Clin Invest; 1979 Aug; 64(2):559-60. PubMed ID: 110835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective antiplatelet drug concentrations in experimental arterial thromboembolism.
    Bjornsson TD; Hanson SR; Harker LA
    Thromb Res; 1987 Nov; 48(3):337-48. PubMed ID: 3433258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of platelet cyclooxygenase inhibition.
    Patrono C; Ciabattoni G; Patrignani P; Pugliese F; Filabozzi P; Catella F; Davì G; Forni L
    Circulation; 1985 Dec; 72(6):1177-84. PubMed ID: 3933848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of dipyridamole.
    Harker LA; Kadatz RA
    Thromb Res Suppl; 1983; 4():39-46. PubMed ID: 6356465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
    Jobin F
    Union Med Can; 1976 Aug; 105(8):1159-73. PubMed ID: 10662
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
    Butler KD; Butler PA; Shand RA; Ambler J; Wallis RB
    Thromb Res; 1987 Mar; 45(6):751-61. PubMed ID: 3109067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
    Moncada S; Korbut R
    Lancet; 1978 Jun; 1(8077):1286-9. PubMed ID: 78050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and other platelet-aggregation inhibiting drugs.
    Gallus AS
    Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
    Lam JY; Chesebro JH; Steele PM; Heras M; Webster MW; Badimon L; Fuster V
    Circulation; 1991 Aug; 84(2):814-20. PubMed ID: 1830520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
    Lorenz R; Siess W; Weber PC
    Eur J Pharmacol; 1981 Apr; 70(4):511-8. PubMed ID: 7238575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action.
    Pedersen AK; FitzGerald GA
    Circulation; 1985 Dec; 72(6):1164-76. PubMed ID: 3905047
    [No Abstract]   [Full Text] [Related]  

  • 14. Human equivalent doses of platelet inhibitors and experimental atherosclerosis.
    Mittal SR; Mathur AK; Tandon R
    Int J Cardiol; 1990 May; 27(2):275-6. PubMed ID: 2365516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proceedings: Comparison of in vivo and in vitro effects of platelet function suppressing drugs.
    Buchanan M; Hirsh J
    Thromb Diath Haemorrh; 1975 Nov; 34(2):552. PubMed ID: 1198423
    [No Abstract]   [Full Text] [Related]  

  • 16. [Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
    Oelz O
    Schweiz Med Wochenschr; 1979 Mar; 109(10):348-53. PubMed ID: 424707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
    Turpie AG
    Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors.
    Slichter SJ; Weiden PL; O'Donnell MR; Storb R
    Blood; 1982 Jun; 59(6):1252-8. PubMed ID: 6805531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy for vascular prosthesis: an experimental model testing platelet inhibitory drugs.
    McCollum CN; Crow MJ; Rajah SM; Kester RC
    Surgery; 1980 Jun; 87(6):668-76. PubMed ID: 6445604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
    Sakata C; Kawasaki T; Kato Y; Abe M; Suzuki K; Ohmiya M; Funatsu T; Morita Y; Okada M
    Thromb Res; 2013 Jul; 132(1):56-62. PubMed ID: 23522855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.